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Introduction
 Gastric cancer is particularly common in East Asian 
countries such as Japan, Korea, and China (Leung et 
al., 2008). The high mortality from gastric cancer is due 
primarily to late presentation. Recently, the diagnosis 
of early gastric cancer has increased and endoscopic 
treatments, such as endoscopic mucosal resection and 
endoscopic submucosal dissection, have increased the 
long-term outcomes and quality of life of patients with 
early gastric cancer (Park et al., 2011). Because of 
this more favorable prognosis of early gastric cancer, 
systematic mass screening of gastric cancer has been 
provided in Japan and Korea (Choi et al., 2011). Attributed 
to the mass-screening program in Japan, early gastric 
cancer represented 50% and 68% of all gastric cancer 
in 1950-1990 and in 2004, respectively (Nishi et al., 
1995; Committee of National Statistics, 2007). In Korea, 
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Abstract
 Background: Although screening is necessary where gastric cancer is particularly common in Asia, the 
performance outcomes of mass screening programs have remained unclear. This study was conducted to evaluate 
cost-effectiveness outcomes of the national cancer screening program (NCSP) for gastric cancer in South Korea. 
Materials and Methods: People aged 40 years or over during 2002-2003 (baseline) were the target population. 
Screening recipients and patients diagnosed with gastric cancers were identified using the NCSP and Korea 
Central Cancer Registry databases. Clinical outcomes were measured in terms of mortality and life-years saved 
(LYS) of gastric cancer patients during 7 years based on merged data from the Korean National Health Insurance 
Corporation and National Statistical Office. We considered direct, indirect, and productivity-loss costs associated 
with screening attendance. Incremental cost-effectiveness ratio (ICER) estimates were produced according to 
screening method, sex, and age group compared to non-screening. Results: The age-adjusted ICER for survival 
was 260,201,000-371,011,000 Korean Won (KW; 1USD=1,088 KW) for the upper-gastrointestinal (UGI) tract 
over non-screening. Endoscopy ICERs were lower (119,099,000-178,700,000 KW/survival) than UGI. To increase 
1 life-year, additional costs of approximately 14,466,000-15,014,000 KW and 8,817,000-9,755,000 KW were 
required for UGI and endoscopy, respectively. Endoscopy was the most cost-effective strategy for males and 
females. With regard to sensitivity analyses varying based on the upper age limit, endoscopy NCSP was dominant 
for both males and females. For males, an upper limit of age 75 or 80 years could be considered. ICER estimates 
for LYS indicate that the gastric cancer screening program in Korea is cost-effective. Conclusion: Endoscopy 
should be recommended as a first-line method in Korea because it is beneficial among the Korean population. 
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approximately 46-67% of gastric cancers screen-detected 
with endoscopy were early-stage cancers (Choi et al., 
2011). Additionally, 5-year survival was improved if the 
cancers were detected by screening rather than at an open 
access clinic (Whiting et al., 2002).
 Although screening is necessary, mass screening 
methods have shown diverse or unclear outcomes 
in previous studies (Leung et al., 2008). Endoscopic 
screening of a high-risk group, Chinese men between 
60 and 70 years old, was shown to be cost-effective 
in 2003 (Dan et al., 2006). In Japan, an indirect X-ray 
method was more cost-effective than direct radiography 
and endoscopy in a 1995 report (Babazono and Hillman, 
1995).Photofluorography screening methods have also 
shown a decrease in gastric cancer mortality among 
the group screened (Miyamoto et al., 2007). Combined 
screening of serum pepsinogen testing and barium digital 
radiography was more effective for a high-risk population 
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in Japan (Ohata et al., 2005). In Iran, performance of 
national-level endoscopy screening was effective for a 
high-risk region.(Mansour-Ghanaei et al., 2012) The cost-
effectiveness of mass screenings may also vary according 
to the cost of the screening examination. For example, 
endoscopic screening costs in Korea are less than 50% of 
those in other countries, like Japan and Singapore (Chang 
et al., 2012).
 Currently, in Korea, direct upper-gastrointestinal X-ray 
(a “UGI series”) or endoscopy has been recommended 
biennially for people 40 years and older since the 
implementation of the National Cancer Screening Program 
(NCSP) in 1999 (Kim et al., 2011). The NCSP was 
expanded to go beyond Medicaid recipients from 2002, 
and since then, the performance outcomes of endoscopy 
and a UGI series as vehicles of a mass screening 
program for gastric cancer have remained unclear. 
A cost-effectiveness outcome is affected by costs, 
clinical outcomes, and participation rates in screening. 
Thus, identifying cost-effective approaches to promote 
population-based screening is important, but there are only 
a few reports about the subject (Andersen et al., 2004).
 In this study, we investigated the impact of the current 
NCSP for gastric cancer by taking both costs and survival 
outcomes into account. The 7-year survival and life years 
saved were assessed to determine the improved outcomes 
of gastric cancers detected through the mass screening 
program. Costs related to gastric cancer screening were 
considered in examining the incremental cost for the 
additional outcome of a UGI series and endoscopy versus 
not screening.
 
Materials and Methods
Study population and data sources
 The study population was Koreans aged 40 years and 
older in 2002-2003 (baseline). The target population and 
participation in NCSP in the baseline years were identified 
through the NCSP database. People who underwent the 
NCSP with a UGI series or endoscopy in 2002 or 2003 
(baseline) were assigned to UGI or Endoscopy groups, 
respectively. People who had not been diagnosed with 
gastric cancer at baseline and did not participate in the 
NCSP for gastric cancer in not only 2002 or 2003 but also 
the following 7 years were assigned to the non-screened 
group. The gastric cancer diagnosis in these three groups 
at baseline and during the 7-year follow-up was examined 
by linking to the Korean Central Cancer Registry database.
 Mortality information during the 7-year follow-up 
period was obtained by merging two national databases 
from the Korean National Health Insurance Corporation 
and the National Statistical Office. Cost data related to 
the gastric cancer screening directly or indirectly were 
collected from the internal accounts of screening units 
in hospitals, published studies, and national statistics. 
Finally, a comparison of survival outcomes following 
7-year outcomes, until 2009 or 2010, was made across 
age groups.
Cost-effectiveness analyses
 To determine the cost-effectiveness of UGI and 
endoscopy, the cost and effectiveness outcomes of each 
group were compared with the non-screened group. Cost 
Table 1. Cost Data for the Analyses
Costs Amount Source
UGI series screening including consultation fee KW 46,190 National Cancer Screening Program guidebook 2002-2011.
Endoscopic screening including consultation fee KW 44,950 Division of Cancer Policy, Ministry of Health and Welfare.
Further testing due to false-positive results from KW 92,564  (a) (b): National Cancer Screening Program guidebook
 the NCSP for UGI group: (a) Endoscopy (44,950+27,910+19,704)    2002-2011. Division of Cancer Policy, Ministry of Health 
  + (b) biopsy+ (c) consultation fee     and Welfare
 (supposing 50% of visits were made   
 with a designated oncologist)  
Further testing due to false-positive KW 47,614 (c): Obtained from the Division of Medical
 results from the NCSP for UGI (27,910+19,704)    Information and Technology, Yonsei University Health
 group: (b) biopsy + (c) consultation fee     System, Seoul
 (supposing 50% of visits were made 
 with a designated oncologist)
Transportation for a visit (round-trip) KW 11,172 The Third Korea National Health and Nutrition 
      Examination Survey (KNHANES III), 2005
Productivity loss costs for half day due to  Statistics Korea, 2009-2011. Ministry of Employment and
 screening test or further examination     Labor, Employment Policy Office
Equation: (average daily wage × economic   Park et al. A Study on the Estimation of Cost Related to
 activity rate + daily wage for housework     Cancer Care and Burden of Cancer Diseases 2003. 
 × non-economic activity rate) × ½     National Cancer Center
       (1) For males  
             Age 40-49 KW 67,408 
             Age 50-59 KW 56,897 
             Age over 60 KW 23,513 
       (2) For females  
             Age 40-49 KW 35,341 
             Age 50-59 KW 30,827 
             Age over 60 KW 25,478 
*All costs were for 2009 or were adjusted to 2009 values
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data used in the cost-effectiveness model are presented in 
Table 1. 
 Three combinations were considered in the cost-
effectiveness models of this study. For COST I, only 
costs directly related to screening were considered, such 
as screening costs and further examination costs after 
false-positive results from the NCSP (Ministry of Health 
and Welfare, 2002-2011). Transportation costs, needed 
for screening attendance or follow-up examination costs, 
were considered as indirect screening costs and COST 
II consisted of direct and indirect screening costs (The 
Third Korea National Health and Nutrition Examination 
Survey (KNHANES Ⅲ), 2005). COST III included all 
costs in COST II plus productivity loss, defined as loss 
of salary due to absence from work to participate in the 
NCSP for gastric cancer. The average daily wage was 
calculated by dividing the annual average salary of each 
age group by the number of working days within 1 year 
(Statistics Korea 2009-2011). For women, even if they did 
not have economic activity, the daily wage of housework 
was considered for calculating their productivity loss 
costs, supposing that women’s labor as housewives would 
have continued (Park et al., 2003). The productivity 
loss cost due to screening attendance was assumed as 
approximately half of the average daily wage, weighted 
for economic and non-economic activity rates (Table 1). 
COST I, COST II, and COST III were applied only to 
the screened groups of NCSP. All costs were inflated to 
values for the year 2009 using the National Consumer 
Indexes (Statistics Korea, 2012). For the base-case cost-
effectiveness analysis, COST III was used.
 As effectiveness measures of NCSP, 7-year survival 
and life-years saved (LYS) within 7 years from the 
baseline years for people with gastric cancers were 
examined. People who had no mortality record during the 
follow-up period were assumed to live until the last year 
of their life expectancy.
 Both effectiveness outcomes and costs were presented 
per 100,000 people in each age group for comparison. 
The outcome information for the entire population 
was age-adjusted for the standard population in Korea.
(Korean Statistical Information Service (KOSIS), 2012) 
To determine cost-effectiveness of NCSP for gastric 
cancers, costs and effectiveness outcomes in the UGI and 
Endoscopy group were compared with the non-screened 
group according to gender.
 Several scenarios were examined as sensitivity 
analyses. First, a scenario with various upper age limits for 
gastric cancer screening in NCSP, which were 60, 65, 70, 
75, and 80, was simulated. Second, it was supposed that 
the cost of an endoscopy examination increased two-fold. 
Third, the average productivity loss cost was assumed to 
increase by 10%. Fourth, although conscious sedation, 
along with endoscopy screening, was not incorporated 
in the base case analysis, it was supposed that 50% of 
endoscopy screenings involved conscious sedation, 
and thus, screening costs for the endoscopy group were 
increased.
 Data management and analyses were performed 
using Microsoft Excel™ and SAS 9.2 software. Figures 
representing incremental costs and effectiveness for 
strategies were made using decision analysis software 
(TreeAge Pro 9.0., TreeAge Software Inc., Williamstown, 
MA).
Results 
Study population
 At baseline, the target population for gastric cancer 
screening was 8,361,420 men and 8,683,567 women. 
Among these, 4.06% and 2.68% of males underwent UGI 
series and endoscopy screening, respectively (Table 2). 
For women, 6.68% underwent a UGI series and 4.64% 
chose endoscopic screening. For both male and female 
participants in NCSP, UGI series were used approximately 
1.5-fold more than endoscopy.
 The proportion of female participants was higher than 
males. Among the target population, approximately 71.8% 
of males and 69.3% of females had never undergone 
gastric cancer screening in NCSP in the 7 years since 
the baseline (Table 2). Males who were younger than 55 
years or older than 75 years at baseline were less likely 
to participate in the NCPS (the proportion in the non-
screening group was over 70%). Males whose age was 
between 60 and 74 in the baseline years participated in the 
NCSP more than other age groups and yet approximately 
60% of them had not participated in gastric cancer 
screening over the 7 years. Women in their 50s and 60s 
participated most in the NCSP for gastric cancer versus 
other age groups. Similar to men, the non-participation 
rate in NCSP was over 88% for females aged 75 years and 
older (Table 2).
Survival and life-years saved outcomes of NCSP versus 
non-screening
 The survival outcome from gastric cancer was highest 
for the Endoscopy group for both males and females. The 
non-screening group had the lowest survival outcome, 
worse than the UGI and endoscopy groups. Per 100,000 
men, the age-adjusted gastric cancer mortality rate in the 
UGI, endoscopy, and non-screening groups was 384, 365, 
and 429 (Figure 1). The gastric cancer mortality was lower 
for females than males and on average, 152, 100, and 176 
females died in the UGI, endoscopy, and non-screening 
groups, respectively.
Table 2. Screening Participation Rates in 2002-2003
Age                     Males                                  Females
group UGI Endoscopy Non- UGI Endoscopy Non-
 series  screening series  screening
40-44 3.37% 2.21% 77.61% 0.58% 4.04% 70.08%
45-49 3.30% 2.49% 78.61% 6.75% 4.66% 66.84%
50-54 4.56% 2.96% 73.38% 8.07% 5.72% 62.61%
55-59 5.26% 3.20% 65.74% 8.87% 6.16% 61.88%
60-64 6.19% 3.56% 59.79% 8.60% 6.13% 63.01%
65-69 6.40% 3.24% 60.80% 7.59% 5.13% 68.94%
70-74 5.05% 2.26% 58.17% 5.55% 3.38% 77.17%
75-79 4.93% 1.69% 83.20% 3.23% 1.87% 88.84%
≥80 2.70% 0.69% 93.08% 1.18% 0.78% 98.33%
Total 4.06% 2.68% 71.81% 6.68% 4.64% 69.31%
*People in the non-screening group did not participate in the National Cancer 
Screening Program for 7 years from the baseline of 2002-2003. Total participation 
rates were age-adjusted
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 The survival outcomes were greater for younger 
age groups (Figure1). For men aged over 75, negative 
7-year survival outcomes were shown for both UGI and 
endoscopy screening, compared with people who had 
never taken part in NCSP cancer screening 7 years after 
baseline. The same result was found for women undergoing 
UGI screening in 2002-2003. The age-adjusted number of 
gastric cancer survivors was increased for both UGI and 
endoscopy groups versus the non-screening group. The 
age-adjusted incremental life saved for males was 44.72 
in the UGI group and 64.19 in the endoscopy group versus 
the non-screening group per 100,000 people (Table 3). For 
female participants, the incremental survival outcome of 
UGI was lower (24.58) than in males, but the survival 
outcome in endoscopy screening was larger (76.25) than 
in males. Thus, the relative effect of endoscopy screening 
compared with a UGI series on gastric cancer survival 
outcome was larger in women than men.
 Regarding life-years saved, the endoscopy screening 
group of men showed the greatest incremental outcome 
(1,367 years) per 100,000 people after age adjustment 
(Table 3). Endoscopy (1,035 years) screening was a better 
strategy than UGI (670 years) for females, considering 
the LYS on an age-adjusted average. Like the survival 
outcome, the outcome of life-years gained was inferior 
for males over 75 years in the UGI and endoscopy groups 
and for females over 75 years in the UGI group compared 
with the non-screening group.
 
Cost-effectiveness analysis of NCSP versus non-screening
 The incremental cost-effectiveness ratios of a UGI 
or endoscopy strategy over non-screening are presented 
in Table 3. The age-adjusted incremental cost per one 
survivor of gastric cancer in the UGI screening group was 
Figure 1. Seven-year Mortality in Gastric Cancer for 
UGI Series, Endoscopy, and Non-screened Groups 
between Males andFemales (per 100,000 people). Total 
frequency values were age-adjusted
Table 3. Incremental Cost-effectiveness Ratios of NCSP of Gastric Cancer Versus the Non-screening Group (per 
100,000 people)
 Costs Age                UGI series vs. Non-screening group                           Endoscopy vs. Non-screening group
 group No. gastric ICER Life years ICER  No. gastric ICER Life years ICER
  cancer deaths  (1000 saved (1000l cancer deaths  (1000 saved (1000
  averted KW/survival)  KW/survival) averted KW/survival)  KW/survival)
No. gastric cancer deaths averted ICER (1000 KW/ survival) Life years saved ICER (1000 KW/ LYS)
Male COST I Total 44.72 112,775 844 5,973 64.19 74,556 1,367 3,500
 COST II Total 44.72 138,874 844 7,356 64.19 92,964 1,367 4,364
 COST III Total 44.72 260,201 844 13,782 64.19 178,700 1,367 8,389
  40-44 14.79 887,205 455 28,838 15.98 819,455 471 27,808
  45-49 17.49 757,872 394 33,671 31.30 420,421 774 16,989
  50-54 57.64 211,248 1,220 9,979 87.03 137,821 1,866 6,429
  55-59 54.48 224,122 873 13,982 99.98 119,818 1,759 6,809
  60-64 133.17 65,410 1,841 4,731 285.75 29,352 3,872 2,166
  65-69 185.62 46,942 1,825 4,775 149.45 56,422 1,502 5,616
  70-74 230.70 37,629 1,578 5,502 435.37 19,275 3,468 2,420
  75-79 -285.63 -- -994 -- -202.00 -- -644 --
  ≥80 -497.19 -- -1,164 -- -1420.50 -- -3,806 --
Female COST I Total 24.58 196,610 670 7,214 76.25 62,636 1,035 4,613
 COST II Total 24.58 243,172 670 8,922 76.25 77,697 1,035 5,722
 COST III Total 24.58 371,011 670 13,614 76.25 119,099 1,035 8,772
  40-44 -0.59 -- -25 -- 7.96 1,204,856 295 32,538
  45-49 33.20 288,162 1,051 9,102 8.60 1,117,171 272 35,331
  50-54 27.57 330,791 768 11,880 30.83 295,637 838 10,878
  55-59 56.59 161,656 1,335 6,853 69.12 131,959 1,612 5,657
  60-64 39.61 217,329 745 11,551 92.61 92,138 1,744 4,892
  65-69 118.59 72,644 1,681 5,124 131.03 64,948 1,764 4,825
  70-74 103.29 83,524 1,063 8,114 241.19 35,170 2,481 3,418
  75-79 -8.28 -- -353 -- 168.94 50,002 1,015 8,319
  ≥80 -294.72 -- -1,494 -- 308.12 27,318 1,408 5,980
*Total values for effects and ICERs were age-adjusted. The survival and life years gained outcomes were observed for 5 years from the screening in 2002-2003. -- denotes 
that NCSP is dominated by the non-screening strategy. All cost estimates were adjusted to 2009 values (exchange rate November 2012: 1 USD = 1,088 KW). Abbreviation: 
ICER, incremental cost effectiveness ratio; LYS, life years saved
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260,201,000 Korean Won, KW; 1USD=1,088KW) for 
males. In considering COST I and COST II, the ICER was 
112,775,000 and 138,874,000 KW/survival for men with 
UGI screening. Endoscopy screening for males showed 
lower (decreased by 31%) ICER estimates (178,700,000 
KW/survival) than a UGI strategy. For females, the 
endoscopy screening resulted in greater cost-effectiveness 
(ICER=119,099,000 KW/survival) than UGI screening 
(371,011,000 KW/survival). The UGI strategy showed 
smaller incremental costs for saving one life in men 
than women. On the other hand, the ICER of endoscopy 
screening was lower for females than males in saving one 
life from gastric cancer.
 The age-adjusted ICER estimates regarding life-years 
saved with UGI and endoscopy were similar between 
males and females. To save 1 life-year, both UGI and 
endoscopy screening were required, at an additional cost 
of approximately 13,600,000 KW and 8,300,000 KW, 
respectively. Males of age 60 74 had the greatest benefit 
in terms of lowest ICER estimates, between 2,166,000 
KW/LYS and 5,502,000 KW/LYS from screening for 
gastric cancer because the outcomes were not additive 
in screening (Table 3). However, if their age was beyond 
75 years, the NCSP dominated. For females, the UGI 
screening was most cost-effective (5,124,000 KW/LYS) 
for the age group 65-69. Endoscopy screening was more 
cost-effective than UGI for females, with the ICER 
estimates only below 8,000,000 KW/LYS for the age 
group in their 50s and over (Table 4).
Sensitivity analyses
 The output of sensitivity analyses according to age 
categories by 10 years are summarized in Table 4. In 
the base case analyses, an endoscopy strategy had lower 
costs than UGI. When assuming the endoscopy screening-
related costs were increased by doubling the costs or by 
considering conscious sedation use, the gap in ICER 
estimates between endoscopy and UGI was reduced versus 
the base case. However, endoscopy was still a more cost-
effective strategy with lower ICER than a UGI strategy 
for males and females.
 Figure 2 presents the results of the incremental costs 
and the number of deaths averted by UGI and endoscopy 
screenings versus non-screening by supposing different 
upper age limits, from 60 to 80, for males and females. 
For males, the current endoscopy screening with no 
upper age limit and two other endoscopy screenings with 
upper age limits of 75 and 80 were dominant strategies. 
For females, the current NCSP with endoscopy was the 
dominant strategy, with no competition.
 
Discussion
In this study, we investigated the cost-effectiveness of 
gastric cancer screening for 7 years in Korea. The survival 
and life-years gained with a UGI series and endoscopy 
were improved compared to non-screening and incremental 
costs per effectiveness unit seemed to be acceptable. The 
clinical outcome may be a natural consequence, because 
gastric cancer detected through systematic mass screening 
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Table 4. Sensitivity Analyses with Incremental Cost-effectiveness Ratios Regarding Life Years Saved during 7 
years (ICER: 1,000 KW/LYS; 1 USD=1,088 KW)
Age                                              UGI vs. non-screening                                                         Endoscopy vs. non-screening
 Base case Endoscopy Productivity Sedation Base case Endoscopy Productivity Sedation
  cost  loss cost use for  cost  loss cost use for
  increase by  increase by endoscopy  increase by  increase by endoscopy
  twice 10% by 50%  twice 10% by 50%
Male: Total 13,782 13,871 14,466 13,867 8,389 11,677 8,817 10,4 2
 40s 31,009 31,172 32,766 31,164 21,233 28,502 22,464 25,684
 50s 11,425 11,499 12,019 11,495 6,591 9,062 6,943 8,104
 60s 4,571 4,795 4,894 4,793 3,016 4,628 3,110 4,003
 70s 12,555 12,666 12,934 12,661 4,104 6,296 4,232 5,446
 >80 -- -- -- -- -- -- -- --
Female: Total 13,614 13,737 15,014 13,808 8,772 12,929 9,755 11,312
 40s 19,135 19,274 21,062 19,270 33,843 49,021 37,633 42,875
 50s 8,947 9,027 9,965 9,025 7,705 11,341 8,568 9,868
 60s 7,196 7,271 7,897 7,269 4,860 7,313 5,368 6,320
 70s 17,511 17,717 19,214 17,712 4,476 6,750 4,935 5,829
 >80 -- -- -- -- 5,980 9,037 6,578 7,799
*-- denotes that NCSP is dominated by the non-screening strategy
Figure 2. Incremental Survival Outcomes and Costs 
Over Non-screening Group for Gastric Cancer 
Screening Strategies with Different Upper Age Limits
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would include a greater proportion of early stage cancers 
(Choi et al., 2011). However, to our knowledge, this is the 
first report identifying the cost-effectiveness of the current 
mass screening of gastric cancers based on actual data of 
a population-based study population in Korea.
Overall, endoscopy screening was more cost-effective 
than the UGI method because its incremental cost per 
LYS was only 60-64% of the cost of UGI. This finding 
is consistent with previous research showing improved 
efficacy and usefulness of endoscopy compared to UGI 
X-ray screening (Kim et al., 2000; Tsubono and Hisamichi, 
2000). Because the cost of endoscopy examination of 
Korea is considerably lower than the UGI examination 
cost, the incremental costs of endoscopy screening were 
competitive in Korea (Chang et al., 2012). A previous 
report found that until the cost of endoscopy screening 
was 3-fold more than a UGI series, the endoscopy method 
should be the dominant strategy over UGI in Korea (Lee et 
al., 2010). That is, the superior cost-effectiveness outcome 
of endoscopy is dependent on future screening-related 
costs and the practitioner performing the endoscopy 
screening.
Among the NCSP participants in 2002 and 2003, 
more people chose UGI screening rather than endoscopy. 
Although endoscopy was a preferred method for gastric 
cancer screening by the majority of population in Korea 
from survey in 2008 and 2010, people who had undergone 
UGI screening were likely to prefer UGI while people 
with an endoscopy screening within the previous 2 years 
preferred endoscopy for the following screening method 
(Choi et al., 2009; Hahm et al., 2011; Park et al., 2011). 
Dissatisfaction in endoscopy screening participants was 
related to insufficient explanation from the staff and the 
physical environment (Lee et al., 2011). A UGI series 
method may have clinical utility as an alternative for 
people who have discomfort or difficulty in endoscopy 
screening. Nevertheless, considering the dominant cost-
effectiveness of endoscopy, it should be recommended as 
the first-line method in Korea.
With regard to various upper age limits, this research 
found that the current endoscopy screening with no age 
limit was the dominant strategy for males and females. 
Additionally, upper age limits of 75 and 80 years are 
also recommended for screening the male population. 
Indeed, the incidence and mortality risk of gastric cancer 
increased in older people (Ito et al., 2009; Nam et al., 
2009). Meanwhile, considering the greater proportion of 
non-screening among males over 70 years old in 2002 and 
2003 (Table 2), a more intensive screening strategy with 
endoscopy may be needed for the aged, especially those 
with a higher risk of gastric cancers (Chung et al., 2012).
Although the baseline of this study was the initial stage 
at which NCSP expanded its coverage, the participation 
rate in gastric cancer screening was low: 6.74% for males 
and 11.32% for females. The number of participants has 
increased since then, but it still seems that gastric cancer 
screening is underused in Korea (Choi et al., 2009). Thus, 
to promote participation in gastric cancer screening, 
it is recommended that NCSP provides appropriate 
education and intervention, highlighting the superior cost-
effectiveness outcomes of endoscopy while encouraging 
use of both endoscopy and UGI methods rather than 
removing UGI series from the recommendations of NCSP 
(Choi et al., 2009).
Our study has several methodological advantages 
over previous studies. First, the study subjects were not a 
cohort group but the entire population of Korea, subjects 
who underwent NCSP gastric cancer screening in baseline. 
Although there have been a couple of reports investigating 
the cost-utility outcomes of gastric cancer screening, those 
Markov models were constructed based on a hypothetical 
cohort group (Gupta et al., 2011; Chang et al., 2012). 
Using large and absolute data from the whole population, 
this research could produce unconditional performance 
outputs of NCSP with no selection bias.
Second, to examine the effect of the initial NCSP 
screening of gastric cancer over non-screening, we defined 
the subjects in the non-screening group to have no record 
of NCSP participation during the observation period of 7 
years since baseline. Although some people with no NCSP 
participation might have undergone an opportunistic 
screening, in our research, we could measure the actual 
cost-effectiveness outcomes of NCSP for gastric cancer 
screening over non-screening pertaining to organized 
programs.
Our study has some limitations that can be addressed 
in future research. First, because it deviated from the 
objective of our study, the cost-effectiveness outcomes by 
different screening cycles were not investigated. Indeed, 
previous research using a simulated Markov-model 
suggested that annual, rather than biennial, endoscopic 
screening was the most cost-effective for the male 
population in Korea (Chang et al., 2012). The screening 
interval should depend on the growth rate of the cancer. 
Although gastric cancer is preceded by a relatively 
prolonged latency period, (Correa, 2004) the screening 
outcome could be also affected by the failure to detect 
cancer at the time of screening and the capabilities of 
physicians or endoscopists in screening services (Cha et 
al., 2012). A recent report found that although the number 
of gastric cancers detected and interval cancers were a 
little greater in the initial screening round compared with 
the subsequent round, the proportion of early cancer stage 
among detected cancers was greater in the subsequent 
round (Choi et al., 2011). People who receive a negative 
result from NCSP may not pay full attention to symptoms 
or the following screening, and thus the outcome of 
interval cancers may be worse for the screened group. In 
future research, the cost-effectiveness outcomes of gastric 
cancer screenings according to different frequencies and 
intervals of NCPS attendance should be determined.
Second, although the gastric cancer incidence is not 
affected by a mass screening program, socioeconomic 
status or behavioral characteristics of NCSP participants 
may differ from those of people in the non-screening 
group. For example, people who are concerned with cancer 
screening may pay more attention to healthy lifestyle 
than the unconcerned. Although no out-of-pocket cost 
is required for participants to undergo NCSP screening, 
people with higher income levels were more likely to be 
rescreened than medical aid recipients (Hahm et al., 2011; 
Lee et al., 2011). Then, the better outcomes of NCSP may 
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be associated with different risks of the people screened. 
However, considering the significantly greater proportion 
of early stage gastric cancer detected in screening, healthy 
behaviors would not seem to explain the improved 
outcomes from mass screening (Miyamoto et al., 2007).
Third, in this research the ICER estimates were 
determined using survival and LYS while quality adjusted 
life years are often used in evaluating ICER values as an 
integrated effectiveness measure. However, given the 
greater proportion of early stage cancers from screening 
detection, considering the quality of the lengthened 
survived time period would be associated with greater 
difference in effectiveness outcome and thus, the ICER 
estimates would be more favorable with mass screenings. 
Thus, measuring quality of life in gastric cancer patients 
according to different cancer stages should be pursued to 
identify the intrinsic quality of population-based screening 
programs.
Fourth, although several cost types related to screening 
participation were considered in this study, treatment costs 
for gastric cancers were not considered, nor were indirect 
screening costs. Treatment costs may not differ between 
screening and clinic detection. As mentioned above, 
early stage cancers represented an increased share of all 
gastric cancers, and thus, the ICERs including treatment 
costs would be more favorable for a screening strategy 
over non screening. By incorporating treatment costs 
and other costs, such as indirect and productivity loss 
costs, associated with treatments, the cost-effectiveness 
outcomes from subpopulations of society could be 
evaluated.
In our study, we tracked the subjects for 7 years, 
which was the longest follow-up period possible with the 
available data. However, a longer follow-up period, like 
10 or 20 years, may be necessary to determine the ultimate 
outcomes of NCSP in Korea. Additionally, the NCSP 
participation rate and the use of screening methods have 
changed. Furthermore, the epidemiological characteristics 
of gastric cancer, like the incidence, would vary as 
well as cost-related factors. Thus, research on the cost-
effectiveness of NCSP needs to be conducted continuously 
to examine trends in cost-effectiveness outcomes of an 
organized gastric cancer screening scheme. In so doing, 
a better cost-effective recommendation could be made 
within the context of an organized screening program.
In the present study, we evaluated the cost-effectiveness 
outcomes of mass screening for gastric cancer using 
population-based data. Among the strategies, endoscopy 
screening was superior to a UGI series for males 
and females in terms of cost-effectiveness outcomes 
compared to non-screening. These findings may be useful 
in developing a more cost-effective organized cancer 
screening program with improved quality of screening, 
which may result in increased participation and improved 
outcomes of the NCSP in Korea.  
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